Nonclinical Evaluation of Cell and Gene Therapy Products: Process, Safety Assessment, and Metabolic Analysis

Cell and Gene Therapy (CGT) has become one of the most promising emerging sectors in the biopharmaceutical industry. However, due to its distinct characteristics compared to traditional drugs, it poses unique safety risks in manufacturing, non-clinical evaluation, and clinical application.

To enhance the evaluation technologies for cell and gene therapy (CGT) products in China and promote industrial development, this event is jointly hosted by the Drug Toxicology Professional Committee of the Chinese Pharmacological Society, Tsinghua University Press, and the Drug Toxicology and Safety Evaluation Professional Committee of the Chinese Society of Toxicology, and organized by Guoke Yisai (Beijing) Pharmaceutical Technology Consulting Co., Ltd.Academic Salon on Nonclinical Evaluation of Cell and Gene Therapy Products: Manufacturing Process, Safety Assessment, and Metabolic Analysis, will be held onMay 21, 2022, 13:30Live streaming on the Huoshi Shulian platform.

This conference has invited numerous domestic drug review experts, FDA drug review experts, and experienced field experts. Experts and friends engaged in the research and development of innovative drugs, such as cell and gene therapies, are welcome to attend, listen, and jointly discuss hot topics.

Scan the QR code to watch the live stream

Scan the QR Code to Watch the Live Stream